Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model

Ntokozo S. Dambuza¹*, Peter Smith¹, Alicia Evans¹, Jennifer Norman¹, Dale Taylor¹, Andrew Andayi², Timothy Egan², Kelly Chibale² and Lubbe Wiesner¹

Abstract

**Background:** During the erythrocytic stage in humans, malaria parasites digest haemoglobin of the host cell, and the toxic haem moiety crystallizes into haemoglobin. Chloroquine acts by forming toxic complexes with haem molecules and interfering with their crystallization. In chloroquine-resistant strains, the drug is excluded from the site of action, which causes the parasites to accumulate less chloroquine in their acid food vacuoles than chloroquine-sensitive parasites. 3-Hydroxylpyridin-4-ones are known to chelate iron; hydroxypyridone-chloroquine (HPO-CQ) hybrids were synthesized in order to determine whether they can inhibit parasites proliferation in the parasitic digestive vacuole by withholding iron from plasmodial parasite metabolic pathway.

**Methods:** Two HPO-CQ hybrids were tested against *Plasmodium falciparum* chloroquine-sensitive (D10 and 3D7) and -resistant strains (Dd2 and K1). The pharmacokinetic properties of active compounds were determined using a mouse model and blood samples were collected at different time intervals and analysed using LC–MS/MS. For in vivo efficacy the mice were infected with *Plasmodium berghei* in a 4-day Peters’ test. The parasitaemia was determined from day 3 and the course of the infection was followed by microscopic examination of stained blood films every 2–3 days until a rise in parasitaemia was observed in all test subjects.

**Results:** IC₅₀ values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively. Pharmacokinetic evaluation of these compounds showed low oral bioavailability and this affected in vivo efficacy when compounds were dosed orally. However, when dosed intravenously compound 1 showed a clearance rate of 28 ml/min/kg, an apparent volume of distribution of 20 l/kg and a half-life of 4.3 h. A reduction in parasitaemia was observed when compound 1 was dosed intravenously for four consecutive days in *P. berghei*-infected mice. However, a rise in parasitaemia levels was observed on day 6 and on day 9 for chloroquine-treated mice.

**Conclusion:** The hybrid compounds that were tested were able to reduce parasitaemia levels in *P. berghei*-infected mice when dosed intravenously, but parasites recrudesced 24 h after the administration of the least dose. Despite low oral bioavailability, the IV data obtained suggests that further structural modifications may lead to the identification of more HPO-CQ hybrids with improved pharmacokinetic properties and in vivo efficacy.

**Keywords:** Malaria, Pharmacokinetics, Hydroxypyridone-chloroquine, In vivo efficacy

*Correspondence: ntokozo.dambuza@telkomsa.net

¹ Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa

Full list of author information is available at the end of the article

© 2015 Dambuza et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Malaria is a disease caused by an eukaryote parasite of the genus *Plasmodium* and remains a major global public health problem, that was responsible for 584,000 deaths in 2013, with most occurring in Africa and most deaths in children under 5 years of age [1, 2]. *Plasmodium falciparum* and *Plasmodium vivax*, are responsible for most cases of malaria and the control of these parasites by chloroquine and other known anti-malarial drugs has been compromised by the emergence and spread of drug resistance in many parts of the world, primarily in *P. falciparum* strains [3, 4]. This has severely limited the use of many effective anti-malarials, and has become a major threat to malaria elimination efforts, causing increased morbidity and mortality and a financial burden due to sustenance of replacement therapy [3].

When the parasite infects the erythrocyte, it uses the endolysosomal system to digest the haemoglobin in an acidic food vacuole, producing an oxidized form of haem, ferriprotoporphyrin IX (FP-IX), which is the iron containing non-protein component of haemoglobin, as a by-product [5–7]. Free FP-IX is toxic and can lyse the cell and affect the function of lysozomal enzymes. The parasite disposes the toxic FP-IX by a polymerization process that crystallizes at least 95 % of FP-IX as haemozoin, and this allows an uninterrupted growth and proliferation of the parasite [8–10]. Iron chelators have been studied as alternative malaria drugs for many years because of their ability to interact with available iron in the nucleus and parasite cytosol, thereby interfering with the iron-dependent metabolism of malaria parasites and inhibiting their development [11, 12].

Hydroxypyridones are iron-chelating agents known to suppress malaria growth in vivo and in vitro [13, 14]. Both hydroxypyridones and chloroquine target the erythrocytic stage of the malaria life cycle, which is highly dependent on iron. For the purpose of this study, *N*-alkyl-3-hydroxypyridin-4-ones were combined with chloroquine in an attempt to enhance antiplasmodial effect against chloroquine-resistant strains of *P. falciparum* when compared to inhibition by chloroquine alone [13]. Compound 1 and 2 were selected among a series of hydroxypyridone-chloroquine (HPO-CQ) hybrid compounds in order to assess their antiplasmodial activity in vitro and efficacy in vivo and to evaluate their pharmacokinetic properties.

**Methods**

**In vitro antiplasmodial activity against chloroquine-sensitive and resistant strains**

The human parasite *P. falciparum* strains used in this study were chloroquine-sensitive (CQS) (3D7 and D10) and chloroquine-resistant (CQR) (Dd2 and K1) and were obtained from the malaria reagent depository, Malaria Research and Reference Reagent Resource Center (MR4) (ATCC, Manassas, VA, USA). The parasites were continuously cultured in vitro according to the method described by Trager and Jensen but with modifications [15]. The cultures were maintained at 37 °C in O-positive (O+) human erythrocytes in complete culture medium, which contained RPMI 1640 (Gibco-BRL Laboratories) growth medium supplemented with 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (Sigma-Aldrich Chemical Company) buffer, 22 mM glucose (Sigma), 5 g/l albumax (Gibco-BRL Laboratories), 25 mM sodium carbonate (Sigma) and 0.3 mM hypoxanthine (Sigma). In order to control microbial contamination 50 µg/l gentamicin (Sigma) was added to the culture medium, and to obtain a loosely synchronous ring stage, 5 % sterile aqueous α-sorbitol (Sigma) was used. The antiplasmodial assay was initiated with the parasites in the trophozoite stage and with a parasitaemia and haematocrit of 2 %.

The test compounds were tested at a concentration range of 0.15–150 mM and chloroquine (Sigma) was tested at a concentration range of 0.003–3 and 0.0003–0.3 mM for resistant strain and sensitive strains, respectively. Non-parasitized erythrocytes were used as a negative control and parasitized erythrocytes, without any test compound, were used as positive control. A full day dose–response was performed for all compounds to determine the concentration inhibiting 50 % of parasite growth (IC50 value). The plates were incubated for 48 h at 37 °C in a gassing chamber containing a mixture of 5 % CO2, 3 % O2 and 92 % N3. In order to quantify parasite viability and to determine the effect of the compounds on the parasite, a parasite lactate dehydrogenase (pLDH) assay was used as described by Makler et al. [16, 17], but with modifications.

**Pharmacokinetic studies**

A comprehensive pharmacokinetic (PK) study of compound 1 and 2 was performed on 10-week old male and female C57BL/6 mice (20–30 g) obtained from the University of Cape Town Medical School Animal Unit. The mice were housed in ventilated cages at room temperature (approximately 22 °C) with constant supply of food and water and were monitored twice daily. The study was authorized by the Faculty of Health Science Animal Research Ethics Committee before commencement: Reference No. 012/020. All the work was performed according to the guidelines established by Austin et al. [18].

The compounds were prepared in oil-in-water (o/w) microemulsions, which consist of 5 % ethyl linoleate (Sigma), 11 % Tween 80 (Sigma), 4 % ethanol (Merck), and 80 % water. In each experiment a group of five
animals were dosed orally (10 ml/kg) at 20 mg/kg and intravenously (5 ml/kg) via the dorsal penile vein at 4 mg/kg under anaesthesia. For oral dosage, a gavage needle was used for the administration of test compounds directly into the lower oesophagus or stomach. Blood samples (approximately 30 µl) were collected serially by needle prick on the tail vein, near to the tip of the tail, at 0, 0.17, 0.5, 1, 2, 3, 5, 7, and 9 h post-dosing. Lithium heparin-coated MiniCollect® Plasma Tubes (Lasec, South Africa) were used to collect the blood samples. The collected blood samples were placed on ice immediately after sampling, and were frozen at −80 °C until analysis.

**Sample preparation**
The blood samples stored at −80 °C were thawed at room temperature and then mixed by vortex to ensure homogeneity. Twenty µl of blood was mixed with 50 µl Milli-Q water (Millipore, USA) and 150 µl acetonitrile (Merck). The mixture was vortexed for 15 s, sonicated for 10 min and centrifuged at 13,000 g for 5 min. The supernatant was transferred to a flat-bottomed glass insert and placed in a glass vial and placed in the autosampler for analysis.

**Liquid chromatography–mass spectrometry summary**
A liquid chromatography–mass spectrometry (LC/MS/MS) system was employed for the quantification of the compounds in mouse blood. The LC system employed was an ultra-fast liquid chromatography (UFLC) system (Shimadzu) and the separation of the compounds was performed on a Phenomenex, Luna 5 µm PFP (2), 100 Å, 50 mm × 2 mm analytical column. The mobile phase A consisted of 0.1 % formic acid in water (v/v) and mobile phase B consisted of acetonitrile. The flow rate was set at 500 µl/min and the temperature of the column was maintained at 40 °C. For the separation of the compounds, the mobile phase was increased from 5 to 95 % B over 4 min, after that, phase B was returned to 5 % within 0.1 min, then equilibrated for 3 min.

The detection of the compounds was performed on an AB Sciex 3200 Q-Trap mass spectrometer which was operated at unit resolution in the multiple reaction monitoring (MRM) mode. The calibration range for all the compounds was operated at unit resolution in the multiple reaction monitoring (MRM) mode. The calibration range for all compounds was between 7.8 and 1000 ng/ml and the accuracy (% Nom) for the calibration curves was between 90.3 and 104.0 %.

| Parameter                  | Compound 1 | Compound 2 |
|----------------------------|------------|------------|
| Q1 mass (Da)               | 531.2      | 490.2      |
| Q3 mass (Da)               | 91.1       | 261.2      |
| Dwell time (ms)            | 40         | 40         |
| Declustering potential (V) | 91         | 61         |
| Collision energy (V)       | 89         | 73         |
| Entrance potential (V)     | 10         | 10         |
| Collision cell exit potential (V) | 4  | 2         |
| Source temperature (°C)    | 500        | 500        |
| Curtain gas (psi)          | 25         | 25         |
| Gas 1 (psi)                | 50         | 50         |
| Gas 2 (psi)                | 70         | 70         |
| CAD gas                    | Medium     | Medium     |
| Ion spray voltage (kV)     | 5500       | 5500       |
| Ionization mode            | Positive   | Positive   |

**Pharmacokinetic analysis**
Non-compartmental analysis was performed on each individual set of data using PK Solutions 2.0 Pharmacokinetic Analysis Software (Summit Research Services, Montrose, USA). The following PK parameters were calculated: apparent terminal half-life [t½ (min)], total exposure [AUC0–α (µM min)], volume of distribution (l/kg) and plasma clearance [CL (l/min/kg)].

**In vivo anti-malarial efficacy of compound 1 against a chloroquine-sensitive Plasmodium berghei strain**
The chloroquine-sensitive Plasmodium berghei (ANKA strain) was used to assess in vivo anti-malarial efficacy of the test compounds. The parasites were maintained in a C57BL/6 mouse by inoculation with 250 µl of a 1:1 (v/v) suspension of erythrocytes infected with P. berghei in phosphate buffered saline (PBS). On the day of the experiment the host mouse was anaesthetized intraperitoneally with a mixture of ketamine (120 mg/kg) and xylazine (16 mg/kg). Whole blood from the host mouse was drawn by cardiac puncture into a Vacuette® heparin tube and a suspension of P. berghei parasitized erythrocytes (1 × 10⁷) in PBS was prepared and the test mice were infected with 200 µl of this suspension intraperitoneally.

Evaluation of the curative potential of the test compounds was performed using Peters’ 4-day test as described [19]. The mice were dosed orally at 20 and 40 mg/kg and intravenously at 4 and 8 mg/kg 2 h post-infection and for three consecutive days (D₃ to D₅). On the first day (D₁), blood samples were collected serially from each mouse at 0.5, 1, 3, and 7 h post-dosing in order to provide quantitative measurements of drug exposure which is needed for the sound interpretation of the efficacy of the anti-malarials [20]. Chloroquine was used as a reference drug and was dosed orally at 10 mg/kg. The mice were also dosed orally with PBS as a control. The parasitaemia was determined from the third day (D₃) by preparing thin blood films from the tail of each mouse.
and the smears were fixed with methanol and stained with Giemsa. This was repeated every 2–3 days to monitor the efficacy of the test compounds. The formula used to calculate % parasitaemia and % reduction is described below, respectively. The data for % parasitaemia and % reduction of parasitaemia is presented in Table 4.

\[
\% \text{ Parasitaemia} = \frac{\text{No. of parasitized RBC out of 500 erythrocytes}}{\text{Total no. of RBC counted}} \times 100
\]

\[
\% \text{ Reduction} = \frac{\text{Parasitamia of placebo} - \text{Parasitamia of test compound}}{\text{Parasitamia of placebo}} \times 100
\]

**Results**

**Antiplasmodial action of the compounds in vitro**

Compounds 1 and 2 were synthesized in order to enhance the activity of chloroquine by combining it with an iron chelator. These compounds were tested for antiplasmodial activity against sensitive strains 3D7 and D10 and resistant strains K1 and Dd2 and the IC₅₀ values (in µM) of compounds 1 and 2 are summarized in Table 2. The P values were calculated using the non-parametric Mann–Whitney U test in order to compare the activity of chloroquine with that of the HPO-CQ hybrids. The resistance index (RI), the ratio of the IC₅₀ of the resistant strain to that of the sensitive strain, was calculated for these compounds using the lowest IC₅₀ value of the sensitive and the highest IC₅₀ of the resistant strain for each compound, which should give the highest RI value for that compound [21]. This value provides a quantitative measurement of the antiplasmodial activity against CQR strains relative to that against CQS strains [22]. The higher the RI value, the higher the level of resistance. The RI value was calculated according to this formula [23]:

\[
\text{Resistance Index (RI)} = \frac{\text{Chloroquine – resistant strain IC₅₀}}{\text{Chloroquine – sensitive strain IC₅₀}}
\]

The IC₅₀ values calculated from the dose response curves were in the range of 0.041–0.064 µM against 3D7 and 0.047–0.122 µM against D10. These values were higher than that of chloroquine, with IC₅₀ values of 0.019 and 0.023 µM against 3D7 and D10, respectively. The IC₅₀ values of the compounds against the resistant strain K1 and Dd2 were compared to those of chloroquine (IC₅₀ values of 0.279 and 0.180 µM for K1 and Dd2, respectively). Compound 2 was more active than chloroquine with IC₅₀ values of 0.089 and 0.076 µM for K1 and Dd2, respectively. Compound 1 on the other hand was less active than chloroquine with IC₅₀ values of 0.505 and 0.463 µM for K1 and Dd2, respectively. The data presented in Table 2 show that the difference in the activity of the HPO-CQ hybrids when compared to chloroquine is insignificant at \( P > 0.05 \) in all chloroquine-sensitive strains. However, activity of the two compounds against the resistant strains differed significantly. The compounds had lower RI values than chloroquine. Compound 2 had an RI value of 2.2, which is over five times less than that of chloroquine and the RI value of compound 1 was 10.7 (Fig. 1).

**Pharmacokinetics**

The compounds were administered to mice orally and intravenously at 20 and 4 mg/kg, respectively. The blood levels for both compounds in the mice dosed orally could not be detected because the values were below the limit of quantitation (LOQ). The concentration versus time intravenously (IV) profiles of both compounds is presented in Fig. 2. The mean concentration–time data were used to calculate the PK parameters by non-compartmental analysis using PK Solutions 2.0 Pharmacokinetic Analysis Software. The PK parameters are presented in Table 3.

Compound 1 showed a clearance rate of 28 ml/min/kg, a high apparent volume of distribution of 20 l/kg and a half-life of 4.3 h. The area under the curve (AUC) value was also at 196 µM min. Even with the half-life of 4.3 h, the compound remained at detectable levels of 0.16 µM.

### Table 2 In vitro IC₅₀ values (µM) of compounds 1 and 2

| Test compounds | Sensitive strains | Resistant strains | RI | P value |
|---------------|-----------------|------------------|----|--------|
|               | 3D7             | D10              | K1 | Dd2    |
| 1             | 0.064 ± 0.02    | 0.047 ± 0.01     | 0.505 ± 0.10 | 0.463 ± 0.12 | 10.7 | 0.343 |
| 2             | 0.041 ± 0.02    | 0.122 ± 0.03     | 0.089 ± 0.01 | 0.076 ± 0.01  | 2.2  | 1     |
| Chloroquine   | 0.019 ± 0.00    | 0.023 ± 0.00     | 0.279 ± 0.002 | 0.180 ± 0.01  | 14.4 | n/a   |

The values obtained from antiplasmodial tests represent the mean of three independent experiments each performed in triplicate.

RI value, values calculated using the highest CQR IC₅₀ value and lowest CQS IC₅₀ value; n/a, not applicable.
after 9 h at the end of the dosing interval, indicating a slow elimination rate from circulation. When considering these properties and IC\textsubscript{50} values of 0.064–0.505 µM against sensitive and resistant strains, respectively, compound 1 was selected for in vivo efficacy studies. Even though the compound could not be detected in blood following an oral dosage, investigating the efficacy of compound 1 after an intravenous dosage was considered.

Compound 2, on the other hand, had a very short half life of 0.7 h and after 2 h the blood levels dropped to 0.03 µM because of a high clearance rate of 366 ml/min/kg. The volume of distribution was also high at 154.1 l/kg.

### Anti-malarial effect of compound 1 on *Plasmodium berghei*-infected mice

The PK evaluation shows that compound 1 and 2 levels were below the LOQ. They both presented poor PK properties following oral administration. However, the LC–MS/MS assay only detected the parent compound and no assays were conducted to measure or identify any possible metabolites. The decision to perform efficacy studies was based on the possibility that compounds 1 and 2 may have high first pass effect which may cause low bioavailability. After the infected mice were dosed orally and intravenously with compound 1 and 2, the blood concentrations were measured in *P. berghei*-infected mice at different time intervals to measure the exposure of the infected mice to the drug. The blood concentration levels of the mice that were dosed orally were below the
detection level in both 20 and 40 mg/kg groups. Figure 3 shows concentration versus time profiles of compound 1 following IV administration in mice infected with *P. berghei*. For compound 2 the IV data showed a very high clearance rate compared to compound 1 and blood concentration levels were very low. High toxicity was also detected when dosed orally and intravenously. The PK studies were only conducted for 9 h, and therefore the symptoms of toxicity were not severe. However, with efficacy studies the mice are dosed every day for 4 days, and this might cause distress to the mice because the toxic effect of the drug will be more severe. The efficacy study for compound 2 is not reported in this paper.

When considering compound 1 blood concentration of healthy animals in Fig. 2a and *P. berghei*-infected animals in Fig. 3, it was noted that higher drug levels were observed in infected mice. It is unlikely that the presence of parasites could be the reason for such a significant difference in blood levels because the mouse exposure study was performed 2 h post infection and parasitized erythrocytes are rapidly absorbed after intraperitoneal inoculation [24]. This difference could possibly be due to the variation in age and weight.

To evaluate the anti-malarial efficacy of compound 1 in infected mice, the parasitaemia level was calculated at days 4, 6 and 9 post infection, and the % reduction of parasitaemia was calculated for day 9 only because parasite levels were observed in all treated mice on day 9.

In the mice that were dosed orally, the parasites were visible at a parasitaemia of ±5 % on day 4. These data correlate well with the PK data because the blood levels of compound 1 following oral dosage were too low to have any effect on reducing parasitaemia, and thus allowing the disease to progress as indicated by a rise in the parasitaemia levels, as shown in Table 4. It was also noted that the parasitaemia in mice that were dosed orally was higher than the parasitaemia in the placebo group. This may mean that high oral doses may cause compound 1 to be immunosuppressive, thus allowing the infection to be severe in the oral group when compared to the placebo group. High parasitemia levels in the 40 mg/kg/day oral group resulted in a negative value of % reduction of parasitaemia (Table 4).

As expected, blood levels remained high for a longer period for mice dosed intravenously with 4 and 8 mg/kg of compound 1 as shown in the concentration versus time profiles in Fig. 3. These data are consistent with the comprehensive PK study presented in Table 3, which shows that compound 1 had a half-life of 4.3 h following intravenous dosage and a clearance rate of 28 ml/min/kg. Figure 3 shows that after 7 h following intravenous dosage the blood concentration levels were relatively high for 4 and 8 mg/kg. This resulted in a reduced parasite multiplication rate as indicated by undetected to low parasitaemia until day 4 and 6. However, the data suggest that compound 1 suppressed the parasitaemia without clearing all parasites, therefore, surviving parasites in the mice blood began to multiply after the 4-day course of treatment, causing a parasite reduction to decrease to 62 and 83 % in the mice dosed at 4 and 8 mg/kg on day 9.

### Table 4 In vivo antiplasmodial efficacy of compounds 1 in C57BL/6 mice blood infected with *P. berghei*

| Test group         | Average % parasitemia | % reduction of parasitemia |
|--------------------|-----------------------|---------------------------|
| Oral (20 mg/kg/day) | 5.3 ± 3.9             | 3.7 ± 5.6                 |
| Oral (40 mg/kg/day) | 5.9 ± 2               | −93.8 ± 49.3              |
| IV (4 mg/kg/day)   | 0.4 ± 0.4             | 61.9 ± 26                 |
| IV (8 mg/kg/day)   | 0 ± 0.9               | 82.9 ± 2.5                |
| Oral CQ (10 mg/kg/day) | 0 ± 0.9           | 92.0 ± 0.4               |
| Placebo            | 2.5 ± 2.4             | –                         |

Data represent mean ± standard deviation of data points obtained from five mice.
respectively, as shown in Table 4. This also shows that the efficacy of compound 1 is dose dependent.

**Conclusion**

The aim of synthesizing HPO-CQ hybrids was to develop anti-malarial candidates that were potent against sensitive and resistant *P. falciparum* strains. This study showed that combining chloroquine with a HPO can cause a change in the physicochemical properties of the hybrid, thus affecting its efficacy and PK properties. Chloroquine alone has an oral bioavailability of 79–90 % and a half-life of 7 h in mice, as reported by Salako [25]. Even though compound 2 was more active than chloroquine in vitro against the resistant strains with a lower RI value, the PK properties were not improved relative to chloroquine. Compound 1 was less active in vitro against the resistant strains than compound 2 and chloroquine with poor oral bioavailability, but it proved to be an effective anti-malarial compound in vivo when dosed intravenously. Nevertheless, chloroquine remained more effective in vivo than both compounds and this means that further modifications on the chemical structure could improve PK properties, such as oral bioavailability, thus improving efficacy.

**Abbreviations**

AUC: area under the curve; CL: clearance; CQ: chloroquine; CQR: chloroquine resistant; CQS: chloroquine sensitive; Da: Daltons; FP-IX: ferriprotoporphyrin; AUC: area under the curve; CL: clearance; CQ: chloroquine; CQR: chloroquine resistant; CQS: chloroquine sensitive; Da: Daltons; FP-IX: ferriprotoporphyrin; HPLC: high-performance liquid chromatography; MRM: multiple reaction monitoring; RBC: red blood cells; RI: resistance index; T1/2: half-life; UFLC: ultra-fast liquid chromatography; Vss: volume of distribution.

**Authors’ contributions**

ND participated in research design, conducted in vitro and in vivo experiments, interpreted the data and wrote the manuscript. PS, KC and LW participated in research design and contributed to the writing of the manuscript. AE developed and validated the LC–MS/MS assay for the quantitative determination of compounds 1 and 2 in mouse blood. DT performed in vivo efficacy experiments. JN assisted with the evaluation of the PK-properties using PK-summit software. AA and TE synthesized the compounds. All authors read and approved the final manuscript.

**Author details**

1 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa. 2 Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7700, South Africa.

**Acknowledgements**

The authors acknowledge Mr Trevor Finch for assisting with animal handling. The University of Cape Town, Clinical Infectious Diseases Research Initiative and National Research Foundation, South African Medical Research Council, and South African Research Chairs Initiative of the Department of Science and Technology, administered through the South African National Research Foundation are gratefully acknowledged for support.

**Competing interests**

The authors declare that they have no competing interests.

**Received** 15 July 2015 **Accepted** 2 December 2015

**Published online** 16 December 2015

**References**

1. Prakash A, Sharma SK, Mohapatra PK, Bhattacharjee K, Gogoi K, Gogoi P, et al. In vitro and in vivo antimalarial activity of the root extracts of *Baccaea mollis* Wall. ex Kurz. Parasitol Res. 2013;112:637–42.
2. WHO. World malaria report 2014. Geneva: World Health Organization; 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/.
3. Hastings IM. The origins of antimalarial drug resistance. Trends Parasitol. 2004;20:512–8.
4. Maltha J, Jacobs J. Clinical practice. Eur J Pediatr. 2011;170:821–9.
5. Fitch CD. Involvement of heme in the antimalarial action of chloroquine. Trans Am Clin Climatol Assoc. 1998;109:97–105.
6. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004;74:1953–7.
7. Orjih AU. On the mechanism of hemozoin production in malaria parasites: activated erythrocyte membranes promote β-hematin synthesis. Exp Biol Med. 2001;226:746–52.
8. Combrinck JM, Mabotha TE, Nickaai KK, Ambéle MA, Taylor D, Smith P, et al. Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem Biol. 2012;8:133–7.
9. Egan TJ, Ross DC, Adams PA. Quinoline anti-malarial drugs inhibit spontaneous formation of β-haematin (malaria pigment). FEBS Lett. 1994;352:54–7.
10. Loria P, Miller S, Foley M, Tilley L. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem J. 1999;339:363–70.
11. Ferrer P, Tripathi AK, Clark MA, Hand CC, Reinhoff HY, Sullivan DJ. Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. PLoS One. 2012;7:e37171.
12. Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik Z. Mode of action of iron (III) chelators as antimalarials. II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis. Blood. 1994;84:910–5.
13. Andayi WA, Egan TJ, Gut J, Rosenthal PJ, Chibale K. Synthesis, antiplasmodial activity and β-haematin inhibition of hydroxypyridone-chloroquine hybrids. ACS Med Chem Lett. 2013;4:642–6.
14. Heinsho C, Theanacho E, Spira D, Peter H, Dobbin P, Rider R. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypridin-4-one oral iron chelators. Blood. 1991;77:637–43.
15. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193:673–5.
16. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, Gibbins BL, et al. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg. 1993;48:739–41.
17. Makler MT, Piper RC, Milhous WK. Lactate dehydrogenase and the diagnosis of haem. Parasitol Today. 1998;14:376–7.
18. Austin JC, de Toit D, Fraser N, Lloyd P, Mansfield D, Macleod A, et al. 2004. Guidelines on ethics for medical research: use of animals in research and training. South African Medical Research Council.
19. Peters W. The chemotherapy of rodent malaria. XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizontocidal activity. Ann Trop Med Parasitol. 1975;69:155–71.
20. Jun Tang C, Redmond W. Comparison of serial and parallel blood sampling techniques in mouse pharmacokinetics study. 2nd Asian Pacific SSX Meeting. 2008.
21. Nzila A, Mvuli L. In vitro selection of Plasmodium falciparum drug-resistant parasite lines. J Antimicrob Chemother. 2010;65:390–8.
22. Ekoue-Kovi K, Yearick K, Iwaniuk DP, Natarajan JK, Alumasa J, de Dios A, et al. Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas. Bioorg Med Chem Lett. 2009;17:270–83.

23. Kaushik NK, Sharma J, Sahal D. Anti-plasmodial action of de novo-designed, cationic, lysine-branched, amphipathic, helical peptides. Malar J. 2012;11:256.

24. Patel K, Batty KT, Moore BR, Gibbons PL, Bulitta JB, Kirkpatrick CM. Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria. Antimicrob Agents Chemother. 2013;57:508–16.

25. Salako LA. Pharmacokinetics of antimalarial drugs; their therapeutic and toxicological implications. Ann Ist Super Sanità. 1985;21:15–25.